# Assurant, Inc.: financial statements, quarterly

AIZ · NYSE · CIK 1267238 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/aiz.md) · [Financials](/companies/aiz/financials.md) · [Filings](/companies/aiz/filings.md) · [Insiders](/companies/aiz/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/aiz/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2,774](/filings/0001267238-24-000047.md) | [2,983 d](/filings/0001267238-26-000010.md) | [2,880](/filings/0001267238-25-000026.md) | [2,925](/filings/0001267238-25-000045.md) | [2,968](/filings/0001267238-25-000051.md) | [3,105 d](/filings/0001267238-26-000010.md) | [3,074](/filings/0001267238-26-000027.md) | [3,158](/filings/0001267238-26-000041.md) | [3,232](/filings/0001267238-25-000051.md) | [3,350 d](/filings/0001267238-26-000010.md) | [3,420](/filings/0001267238-26-000027.md) | [3,454](/filings/0001267238-26-000041.md) |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Interest expense | $m | [27.0](/filings/0001267238-23-000052.md) | [26.8 d](/filings/0001267238-24-000008.md) | [26.8](/filings/0001267238-24-000026.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [38.7](/filings/0001267238-24-000047.md) | [44.1 d](/filings/0001267238-26-000010.md) | [56.5](/filings/0001267238-25-000026.md) | [44.2](/filings/0001267238-25-000045.md) | [17.7](/filings/0001267238-25-000051.md) | [48.7 d](/filings/0001267238-26-000010.md) | [37.1](/filings/0001267238-26-000027.md) | [53.7](/filings/0001267238-26-000041.md) | [65.6](/filings/0001267238-25-000051.md) | [58.3 d](/filings/0001267238-26-000010.md) | [61.5](/filings/0001267238-26-000027.md) | [78.3](/filings/0001267238-26-000041.md) |
| Net income | $m | [190](/filings/0001267238-24-000047.md) | [183 d](/filings/0001267238-26-000010.md) | [236](/filings/0001267238-25-000026.md) | [189](/filings/0001267238-25-000045.md) | [134](/filings/0001267238-25-000051.md) | [201 d](/filings/0001267238-26-000010.md) | [147](/filings/0001267238-26-000027.md) | [235](/filings/0001267238-26-000041.md) | [266](/filings/0001267238-25-000051.md) | [225 d](/filings/0001267238-26-000010.md) | [274](/filings/0001267238-26-000027.md) | [299](/filings/0001267238-26-000041.md) |
| Diluted EPS | $ per share | [3.54](/filings/0001267238-24-000047.md) | not reported | [4.47](/filings/0001267238-25-000026.md) | [3.58](/filings/0001267238-25-000045.md) | [2.55](/filings/0001267238-25-000051.md) | not reported | [2.83](/filings/0001267238-26-000027.md) | [4.56](/filings/0001267238-26-000041.md) | [5.17](/filings/0001267238-25-000051.md) | not reported | [5.41](/filings/0001267238-26-000027.md) | [5.95](/filings/0001267238-26-000041.md) |
| Basic EPS | $ per share | [3.55](/filings/0001267238-24-000047.md) | not reported | [4.50](/filings/0001267238-25-000026.md) | [3.59](/filings/0001267238-25-000045.md) | [2.56](/filings/0001267238-25-000051.md) | not reported | [2.86](/filings/0001267238-26-000027.md) | [4.60](/filings/0001267238-26-000041.md) | [5.22](/filings/0001267238-25-000051.md) | not reported | [5.47](/filings/0001267238-26-000027.md) | [5.98](/filings/0001267238-26-000041.md) |

- Revenue: us-gaap:Revenues
- Selling, general and administrative: not reported
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.4](/filings/0001267238-23-000052.md) | [1.6](/filings/0001267238-25-000008.md) | [1.3](/filings/0001267238-24-000026.md) | [1.7](/filings/0001267238-24-000037.md) | [1.8](/filings/0001267238-24-000047.md) | [1.8](/filings/0001267238-26-000010.md) | [1.7](/filings/0001267238-25-000026.md) | [1.5](/filings/0001267238-25-000045.md) | [1.7](/filings/0001267238-25-000051.md) | [1.8](/filings/0001267238-26-000041.md) | [1.6](/filings/0001267238-26-000027.md) | [1.7](/filings/0001267238-26-000041.md) |
| Total assets | $bn | [33.2](/filings/0001267238-23-000052.md) | [33.6](/filings/0001267238-25-000008.md) | [33.2](/filings/0001267238-24-000026.md) | [33.8](/filings/0001267238-24-000037.md) | [35.3](/filings/0001267238-24-000047.md) | [35.0](/filings/0001267238-26-000010.md) | [35.0](/filings/0001267238-25-000026.md) | [35.5](/filings/0001267238-25-000045.md) | [35.8](/filings/0001267238-25-000051.md) | [36.3](/filings/0001267238-26-000041.md) | [35.8](/filings/0001267238-26-000027.md) | [36.1](/filings/0001267238-26-000041.md) |
| Total liabilities | $bn | [28.7](/filings/0001267238-23-000052.md) | [28.8](/filings/0001267238-25-000008.md) | [28.3](/filings/0001267238-24-000026.md) | [28.8](/filings/0001267238-24-000037.md) | [30.1](/filings/0001267238-24-000047.md) | [29.9](/filings/0001267238-26-000010.md) | [29.8](/filings/0001267238-25-000026.md) | [30.0](/filings/0001267238-25-000045.md) | [30.0](/filings/0001267238-25-000051.md) | [30.4](/filings/0001267238-26-000041.md) | [29.9](/filings/0001267238-26-000027.md) | [30.0](/filings/0001267238-26-000041.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $bn | [4.5](/filings/0001267238-24-000047.md) | [4.8](/filings/0001267238-26-000010.md) | [4.9](/filings/0001267238-25-000045.md) | [5.0](/filings/0001267238-25-000051.md) | [5.3](/filings/0001267238-25-000051.md) | [5.1](/filings/0001267238-26-000041.md) | [5.2](/filings/0001267238-26-000041.md) | [5.5](/filings/0001267238-26-000041.md) | [5.8](/filings/0001267238-25-000051.md) | [5.9](/filings/0001267238-26-000041.md) | [5.9](/filings/0001267238-26-000041.md) | [6.1](/filings/0001267238-26-000041.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [331 d](/filings/0001267238-24-000047.md) | [363 d](/filings/0001267238-26-000010.md) | [82.5](/filings/0001267238-25-000026.md) | [711 d](/filings/0001267238-25-000045.md) | [437 d](/filings/0001267238-25-000051.md) | [103 d](/filings/0001267238-26-000010.md) | [392](/filings/0001267238-26-000027.md) | [266 d](/filings/0001267238-26-000041.md) | [505 d](/filings/0001267238-25-000051.md) | [671 d](/filings/0001267238-26-000010.md) | [240](/filings/0001267238-26-000027.md) | [454 d](/filings/0001267238-26-000041.md) |
| Capital expenditure | $m | [50.4 d](/filings/0001267238-24-000047.md) | [54.3 d](/filings/0001267238-26-000010.md) | [50.8](/filings/0001267238-25-000026.md) | [55.4 d](/filings/0001267238-25-000045.md) | [47.1 d](/filings/0001267238-25-000051.md) | [68.0 d](/filings/0001267238-26-000010.md) | [53.4](/filings/0001267238-26-000027.md) | [59.9 d](/filings/0001267238-26-000041.md) | [62.9 d](/filings/0001267238-25-000051.md) | [59.3 d](/filings/0001267238-26-000010.md) | [47.7](/filings/0001267238-26-000027.md) | [45.2 d](/filings/0001267238-26-000041.md) |
| Dividends paid | $m | [37.1 d](/filings/0001267238-24-000047.md) | [38.5 d](/filings/0001267238-26-000010.md) | [37.4](/filings/0001267238-25-000026.md) | [39.9 d](/filings/0001267238-25-000045.md) | [37.5 d](/filings/0001267238-25-000051.md) | [41.1 d](/filings/0001267238-26-000010.md) | [40.9](/filings/0001267238-26-000027.md) | [42.7 d](/filings/0001267238-26-000041.md) | [40.6 d](/filings/0001267238-25-000051.md) | [44.2 d](/filings/0001267238-26-000010.md) | [44.0](/filings/0001267238-26-000027.md) | [47.9 d](/filings/0001267238-26-000041.md) |
| Share repurchases | $m | [49.3 d](/filings/0001267238-24-000047.md) | [126 d](/filings/0001267238-26-000010.md) | [46.1](/filings/0001267238-25-000026.md) | [41.6 d](/filings/0001267238-25-000045.md) | [99.4 d](/filings/0001267238-25-000051.md) | [120 d](/filings/0001267238-26-000010.md) | [64.3](/filings/0001267238-26-000027.md) | [63.3 d](/filings/0001267238-26-000041.md) | [81.8 d](/filings/0001267238-25-000051.md) | [94.3 d](/filings/0001267238-26-000010.md) | [124](/filings/0001267238-26-000027.md) | [77.6 d](/filings/0001267238-26-000041.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [54.1](/filings/0001267238-23-000052.md) | [53.7](/filings/0001267238-24-000026.md) | [53.9](/filings/0001267238-24-000037.md) | [53.7](/filings/0001267238-24-000047.md) | [52.9](/filings/0001267238-25-000026.md) | [52.7](/filings/0001267238-25-000045.md) | [52.5](/filings/0001267238-25-000051.md) | [51.2](/filings/0001267238-26-000027.md) | [51.1](/filings/0001267238-26-000041.md) | [51.3](/filings/0001267238-25-000051.md) | [50.2](/filings/0001267238-26-000027.md) | [49.8](/filings/0001267238-26-000041.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 49,323,767 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001267238-26-000041.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.